MDxHealth SA (MDXH) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, ladies and gentlemen, and welcome to the MDX Health second quarter of 2025 earnings conference call. All participants will be in listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press the star key and then zero on your telephone keypad. Please note that this event is being recorded. I would now like to turn the conference over to John Francis of LifeSci Advisors. Please go ahead. Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factor section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 20F. I'll now turn the call over to Michael McGarrity, Chief Executive Officer. Thanks, Jen. And thank you all for joining us for our Q2 2025 Earnings Conference Call for MDX Health. With me today is Scott McMahon, Interim Chief Financial Officer. We are quite excited to provide an update that reflects our unwavering focus on growth, operating discipline, and commercial execution. Each of these results, both individually and collectively, demonstrate our progress in becoming the growth vertical focused solely into urology in the molecular diagnostic space. We believe MDX Health has clearly established a reputation for consistent growth and execution, as demonstrated by the highlights from our Q2 results that we announced today. Our Q2 revenue of $26.6 million represents 20% growth and marks our 17th consecutive quarter of 20% or...